-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - It-hMSC in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. It-hMSC in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDK-002 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emapalumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emapalumab in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emapalumab in Systemic Lupus Erythematosus Drug Details: Emapalumab (Gamifant) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izalontamab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Izalontamab in Oropharyngeal Cancer Drug Details: SIB-001 is under development for the...
-
Product Insights
Neuromuscular Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromuscular Disorders - Drugs In Development, 2023’, provides an overview of the Neuromuscular Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Muscle Invasive Bladder Cancer (MIBC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Invasive Bladder Cancer (MIBC) - Drugs In Development, 2023’, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Anaplastic Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) - Drugs In Development, 2023’, provides an overview of the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveal Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveal Melanoma - Drugs In Development, 2023’, provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...